CD274 and neoplasm: With checkpoint inhibitors (CPIs) such as anti-PD1 or anti-PDL1, a blocking signal from tumor cells to activated anticancer cytotoxic T lymphocytes (CTLs) is blocked, and hence, the anticancer CTL functioning is deblocked.